Methods for dosing an orally active 1,2,4-oxadiazole
View Patent ↗The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
1. A method for treating or managing a muscular dystrophy associated with a premature stop codon in a human patient, comprising administering to the patient an effective amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in three doses, wherein the three doses comprise a first dose, a second dose and a third dose, and wherein the amounts of the first dose and the second dose are the same and the amount of the third dose is twice the amount of the first dose, in a plurality of 24 hour time periods, wherein the second dose is administered about 6 hours after the first dose is administered, the third dose is administered about 6 hours after the second dose is administered, and the first dose for a next 24 hour time period is administered about 12 hours after the third dose was administered for a preceding 24 hour time period, and wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in a range of about 2 μg/mL to about 20 μg/mL is maintained in said patient for a 24 hour time period.
2. A method for treating or managing a muscular dystrophy associated with a nonsense mutation in a human patient, comprising administering to the patient an effective amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in three doses, wherein the three doses comprise a first dose, a second dose and a third dose, and wherein the amounts of the first dose and the second dose are the same and the amount of the third dose is twice the amount of the first dose, in a plurality of 24 hour time periods, wherein the second dose is administered about 6 hours after the first dose is administered, the third dose is administered about 6 hours after the second dose is administered, and the first dose for a next 24 hour time period is administered about 12 hours after the third dose was administered for a preceding 24 hour time period, and wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof of in a range of about 2 μg/mL to about 20 μg/mL is maintained in said patient for a 24 hour time period.
3. The method of claim 1 or 2 , wherein the first dose, the second dose and the third dose are administered about 30 minutes after a meal.
4. The method of claim 1 or 2 , wherein the doses are administered orally.
5. The method of claim 4 , wherein the doses are administered using one or more unit dosage formulations, wherein the amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in each unit dosage formulation is selected from 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 150 mg, 175 mg, 200 mg, 250 mg, 280 mg, 300 mg, 325 mg, 350 mg, 400 mg, 450 mg, 500 mg, 560 mg, 600 mg, 700 mg, 750 mg, 800 mg, 900 mg, 1000 mg or 1400 mg.
6. The method of claim 4 , wherein the doses are administered using one or more unit dosage formulations, wherein the amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in each unit dosage formulation is selected from 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 175 mg, 200 mg, 250 mg, 280 mg, 350 mg, 400 mg, 500 mg, 560 mg, 700 mg, 750 mg, 800 mg, 1000 mg or 1400 mg.
7. The method of claim 4 , wherein the doses are administered using one or more unit dosage formulations, wherein the amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in each unit dosage formulation is selected from 125 mg, 200 mg, 400 mg or 500 mg.
8. The method of claim 1 , wherein the muscular dystrophy is the result of a premature stop codon in mRNA encoded by the dystrophin gene.
9. The method of claim 2 , wherein the muscular dystrophy is the result of a nonsense mutation in the dystrophin gene.
10. The method of claim 8 or 9 , wherein the expression of dystrophin, sarcoglycan or dystroglycan in the muscle of the patient is increased, the upper or lower extremity myometry in the patient is improved, serum creatine kinase (CK) levels in the patient are decreased or the patient's performance of a functional test is improved.
11. The method of claim 10 , wherein the functional test is a timed ambulatory function test.
12. The method of claim 8 or 9 , wherein the muscular dystrophy is Duchenne Muscular Dystrophy.
13. The method of claim 1 or 2 , wherein each dose administered is in a range of from about 0.1 mg/kg to about 500 mg/kg.
14. The method of claim 13 , wherein each dose administered is in a range of from about 1 mg/kg to about 50 mg/kg.
15. The method of claim 14 , wherein the first dose administered is in a range of from about 2 mg/kg to about 6 mg/kg, the second dose administered is in a range of from about 2 mg/kg to about 6 mg/kg and the third dose administered is in a range of from about 6 mg/kg to about 10 mg/kg.
16. The method of claim 15 , wherein the first dose administered is about 4 mg/kg, the second dose administered is about 4 mg/kg and the third dose administered is about 8 mg/kg.
17. The method of claim 14 , wherein the first dose administered is in a range of from about 5 mg/kg to about 9 mg/kg, the second dose administered is in a range of from about 5 mg/kg to about 9 mg/kg and the third dose administered is in a range of from about 12 mg/kg to about 16 mg/kg.
18. The method of claim 17 , wherein the first dose administered is about 7 mg/kg, the second dose administered is about 7 mg/kg and the third dose administered is about 14 mg/kg.
19. The method of claim 14 , wherein the first dose administered is in a range of from about 8 mg/kg to about 12 mg/kg, the second dose administered is in a range of from about 8 mg/kg to about 12 mg/kg and the third dose administered is in a range of from about 18 mg/kg to about 22 mg/kg.
20. The method of claim 19 , wherein the first dose administered is about 10 mg/kg, the second dose administered is about 10 mg/kg and the third dose administered is about 20 mg/kg.
21. The method of claim 1 or 2 , wherein the first dose is administered in the morning, the second dose is administered at midday and the third dose is administered in the evening of the 24 hour time period.
22. The method of claim 4 , wherein the dose amount is administered using one or more unit dosage formulations each comprising an amount in a range of from about 125 mg to about 1000 mg of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof.
23. The method of claim 4 , wherein the dose amount is administered using one or more unit dosage formulations each comprising an amount in a range of from about 250 mg to about 1000 mg of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof.
24. The method of claim 4 , wherein the dose amount is administered using one or more unit dosage formulations each comprising an amount in a range of from about 500 mg to about 1000 mg of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof.
25. The method of claim 1 , wherein the amount in each unit dosage formulation is selected from 125 mg, 200 mg, 325 mg, 400 mg or 500 mg.
26. The method of claim 1 , wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof of about 2 μg/mL to about 10 μg/mL is maintained in said patient for a 24 hour time period.
27. The method of claim 2 , wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof of about 2 μg/mL to about 10 μg/mL is maintained in said patient for a 24 hour time period.
28. The method of claim 1 , wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof of about 10 μg/mL to about 20 μg/mL is maintained in said patient for a 24 hour time period.
29. The method of claim 2 , wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof of about 10 μg/mL to about 20 μg/mL is maintained in said patient for a 24 hour time period.
30. The method of claim 1 , wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof of about 10 μg/mL is maintained in said patient for a 24 hour time period.
31. The method of claim 2 , wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof of about 10 μg/mL is maintained in said patient for a 24 hour time period.